This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

8 Jun 2020

Vektor Pharma finalizes formula for novel transdermal drug delivery system to treat Parkinson's

Optimizing the dosage form's efficiency reduces the amount of drug required in each patch.

XPhyto Therapeutics’ German subsidiary, Vektor Pharma TF has finalized the formula for its novel transdermal delivery system (TDS) for the neurologic drug Rotigotine, which approved for the treatment of Parkinson's disease and restless legs syndrome in Europe and the US.

Rotigotine, the active pharmaceutical ingredient, is a generic off-patent drug that is typically formulated as a once-daily transdermal patch to provide a slow and constant supply of the drug over the course of 24 hours.

The company claims it has optimized the dosage form efficiency to reduce the amount of drug required in each patch and improved overall patch adhesion to the patient's skin.

Vektor is now focused on process implementation for the manufacture of Rotigotine TDS clinical samples for use in human pilot studies. The parameters for increased manufacturing capacity are currently being evaluated with a final decision expected to be made within 30 days.

Once process implementation is complete, clinical sample manufacturing and analytical work will commence in Vektor's EU GMP laboratory and manufacturing facility based in Baden-Württemberg, Germany. Human pilot studies in Europe are scheduled for Q3 2020 with results expected in Q4 2020.

Related News